Clinical trial
Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in…
NCT00467012 · Chugai Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00467012 |
|---|---|
| Title | Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer |
| Official title | Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer |
| Lead sponsor | Chugai Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab, Paclitaxel |
| Enrollment | 122 |
| Start date | Apr 1, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | Sep 1, 2011 |
| First posted | Apr 27, 2007 |
| Last update posted | Apr 26, 2012 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: